Fluzoparib; Apatinib

Phase 3Small molecule

JJiangsu HengRui Medicine Co., Ltd.

Fluzoparib; Apatinib is one of 53 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Ovarian CancerActive, not recruiting

Breast CancerPhase 3

Active, not recruiting

Ovarian CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Fluzoparib; Apatinib

JJiangsu HengRui Medicine Co., Ltd.

Phase 3

1 2

MS Contin

Merck & Co.

Preclinical

2 3

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 4

Chirocaine

PPurdue Pharma LP

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Vit D

PPost Graduate Institute of Medical Education and Research, Chandigarh

Preclinical

1 10

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Breast Cancer1 trial

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04296370·474 enrolled

Ovarian Cancer1 trial

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04229615·690 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Fluzoparib; Apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluzoparib; Apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluzoparib; Apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu HengRui Medicine Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJiangsu HengRui Medicine Co., Ltd.

Fluzoparib; Apatinib

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Breast Cancer1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News